In conclusion, the data from this systematic review and meta-analysis suggests there is similar anticipated scores for both male and female breast cancer patients undergoing the 21-gene expression assay for ER-positive, HER2-negative breast cancer. This evidence concerns the gene ERBB2 and breast cancer.